000963 华东医药
已收盘 09-10 15:00:00
资讯
新帖
简况
华东医药：积极推进炎朵®中国市场商业化供货事宜
证券之星 · 08:51
华东医药：积极推进炎朵®中国市场商业化供货事宜
瑞银：中国制药股上半年业绩好坏参半 首选先声药业
同花顺 · 09-09 15:58
瑞银：中国制药股上半年业绩好坏参半 首选先声药业
华东医药：依托四大业务推进长期发展
证券之星 · 09-09 15:54
华东医药：依托四大业务推进长期发展
华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出
证券之星 · 09-08 20:52
华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出
华东医药：已搭建人工智能辅助药物发现（AIDD）平台
证券之星 · 09-02
华东医药：已搭建人工智能辅助药物发现（AIDD）平台
华东医药国内医美营收“腰斩”：“少女针”独占红利“破产”，眼窝针等新品难填缺口
蓝鲸财经 · 09-02
华东医药国内医美营收“腰斩”：“少女针”独占红利“破产”，眼窝针等新品难填缺口
股市必读：华东医药（000963）9月1日董秘有最新回复
证券之星 · 09-02
股市必读：华东医药（000963）9月1日董秘有最新回复
华东医药：公司按照上市公司相关监管要求在定期报告中对股东人数予以披露
证券之星 · 09-01
华东医药：公司按照上市公司相关监管要求在定期报告中对股东人数予以披露
华东医药：公司正在应FDA要求，将和FDA进一步讨论HDM2005三期方案设计
证券之星 · 09-01
华东医药：公司正在应FDA要求，将和FDA进一步讨论HDM2005三期方案设计
邦顺制药赴港IPO，创始团队出自华东医药，面临诺华、泽璟制药的竞争
格隆汇 · 09-01
邦顺制药赴港IPO，创始团队出自华东医药，面临诺华、泽璟制药的竞争
国金证券：给予华东医药买入评级
证券之星 · 09-01
国金证券：给予华东医药买入评级
华东医药（000963）披露2026年半年度报告，8月27日股价上涨1.35%
证券之星 · 08-27
华东医药（000963）披露2026年半年度报告，8月27日股价上涨1.35%
华东医药(000963)6月30日股东户数10.02万户，较上期增加18.85%
证券之星 · 08-27
华东医药(000963)6月30日股东户数10.02万户，较上期增加18.85%
股市必读：华东医药新发布《关于全资子公司获得医疗器械注册证的公告》
证券之星 · 08-27
股市必读：华东医药新发布《关于全资子公司获得医疗器械注册证的公告》
华东医药：全资子公司药物获美国FDA快速通道资格
格隆汇 · 08-26
华东医药：全资子公司药物获美国FDA快速通道资格
华东医药最新公告：2026年半年度净利润同比增长2.53%
证券之星 · 08-26
华东医药最新公告：2026年半年度净利润同比增长2.53%
华东医药：全资子公司获含利多卡因注射用交联透明质酸钠凝胶医疗器械注册证
格隆汇 · 08-25
华东医药：全资子公司获含利多卡因注射用交联透明质酸钠凝胶医疗器械注册证
8月21日华东医药跌6.08%，创新药ETF银华基金重仓该股
证券之星 · 08-21
8月21日华东医药跌6.08%，创新药ETF银华基金重仓该股
华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%
证券之星 · 08-17
华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%
华东医药：提议向全体股东每10股派3.50元人民币现金（含税）
证券之星 · 08-17
华东医药：提议向全体股东每10股派3.50元人民币现金（含税）
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":26.62,"timestamp":1789023822000,"preClose":26.98,"halted":0,"volume":9015833,"delay":0,"changeRate":-0.0133,"floatShares":1753000000,"shares":1754000000,"eps":1.9731,"marketStatus":"已收盘","change":-0.36,"latestTime":"09-10 15:00:00","open":26.88,"high":26.89,"low":26.6,"amount":240000000,"amplitude":0.0107,"askPrice":26.62,"askSize":663,"bidPrice":26.61,"bidSize":3264,"shortable":0,"etf":0,"ttmEps":1.9731,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"adjPreClose":26.98,"symbolType":"stock","openAndCloseTimeList":[[1789003800000,1789011000000],[1789016400000,1789023600000]],"highLimit":29.68,"lowLimit":24.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.86,"roa":"--","peRate":13.49146,"roe":"7.31%","epsLYR":1.9484,"committee":0.754366,"marketValue":46684000000,"turnoverRate":0.0051,"status":1,"floatMarketCap":46665000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2666855615","title":"华东医药：积极推进炎朵®中国市场商业化供货事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2666855615","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666855615?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:51","pubTimestamp":1789001467,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：利纳西普获批近两年了，迟迟没有上市销售，公司采取了哪些措施？有哪些进步？还有希望吗？华东医药回复：您好！公司持续与合作方对接炎朵产品供货事宜。针对前期延迟供货对应的和解事项，双方经协商已取得积极进展，并将积极推进中国市场商业化供货事宜。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1969619763.USD","LU2328871848.SGD","BK0175","BK0183","BK0187","BK0188","000963","BK0209","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831405","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831405","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831405?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:58","pubTimestamp":1788940680,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药(03692)、先声药业(02096)、中国生物制药(01177)、石药集团(01093)及科伦 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260909/c679739404.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260909/c679739404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1969619763.USD","BK0188","LU1064131003.USD","BK0132","LU1934453819.USD","LU2328871848.SGD","BK0239","BK0175","BK0060","002422","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","BK0196","BK0187","000963","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666246583","title":"华东医药：依托四大业务推进长期发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666246583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666246583?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:54","pubTimestamp":1788940450,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月09日在投资者关系平台上答复投资者关心的问题。公司依托医药工业、医药商业、医美、工业微生物四大业务推进长期发展：医药工业坚持创新驱动，优化研发管理，持续推进创新药研发与商业化；医药商业向综合药事服务商转型，拓宽非药、代理及分销业务；医美加快海内外产品注册，强化品牌建设与学术推广，持续为求美者提供综合解决方案；工业微生物聚焦大品种，降本增效，拓展海外市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900023501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0132","BK0196","BK0175","BK0209","LU2328871848.SGD","BK0183","BK0188","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373996","title":"华东医药：HDM1002体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373996","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665373996?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:52","pubTimestamp":1788871927,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月07日在投资者关系平台上答复投资者关心的问题。华东医药多款创新药即将亮相 EASD、EADV 与 ESMO 2026 年会。在这些展示的创新产品中并未提及HDM1002,我想问的是因为三期数据没有读出，所以不参展？HDM1002，体重管理适应症中国Ⅲ期临床研究44周主要临床终点数据已顺利读出，后续52周治疗及4周安全随访数据预计今年9月完成，计划今年Q4递交NDA申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800034484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","BK0183","LU2328871848.SGD","BK0132","LU1969619763.USD","BK0196","BK0188","BK0187","BK0175","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664937898","title":"华东医药：已搭建人工智能辅助药物发现（AIDD）平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2664937898","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664937898?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:48","pubTimestamp":1788320887,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月01日在投资者关系平台上答复投资者关心的问题。公司已搭建人工智能辅助药物发现平台，并持续深化在新药研发中的落地应用，推动 AI、生物信息学与研发流程深度融合，赋能靶点评估、分子设计、候选化合物筛选、成药性优化等环节。目前 AIDD 团队已支持近30个在研项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200017684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0175","161631","LU2328871848.SGD","BK0183","BK0187","LU1969619763.USD","000963","BK0188","BK0196","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664089843","title":"华东医药国内医美营收“腰斩”：“少女针”独占红利“破产”，眼窝针等新品难填缺口","url":"https://stock-news.laohu8.com/highlight/detail?id=2664089843","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664089843?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:35","pubTimestamp":1788316558,"startTime":"0","endTime":"0","summary":"华东医药把医美下滑归因为“行业深度调整+自身战略重构阵痛”。华东医药医美核心产品伊妍仕一度风光无限，如今却从“十亿级独家单品”跌回深蹲期的主角。与此同时，行业牌照红利落幕进一步加剧了行业竞争。华东医药也在公告内用“不会对当前财务状况产生重大影响”来形容该产品。若首年只有千万级别销量，这显然很难填补“少女针”下滑留下的缺口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788310786011317510","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664486336","title":"股市必读：华东医药（000963）9月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664486336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664486336?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:08","pubTimestamp":1788282494,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，华东医药报收于27.38元，上涨0.44%，换手率0.73%，成交量12.72万手，成交额3.48亿元。董秘最新回复投资者： 请问公司中报什么时候披露？公司2026年半年度报告已于2026年8月27日披露，二季度具体经营情况详见报告原文。公司按照上市公司相关监管要求在定期报告中对股东人数予以披露。公司正在应FDA要求，将和FDA进一步讨论HDM2005三期方案设计。投资者： 10624三期临床注册快三个月了，国内外都还没完成首例患者入组吗董秘： 您好！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2328871848.SGD","000963","BK0132","BK0183","BK0209","BK0196","BK0187","BK0175","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839388","title":"华东医药：公司按照上市公司相关监管要求在定期报告中对股东人数予以披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664839388?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:06","pubTimestamp":1788246379,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月01日在投资者关系平台上答复投资者关心的问题。公司按照上市公司相关监管要求在定期报告中对股东人数予以披露。此外，公司也可在严格核实股东身份信息后按相关规定告知。若有投资者想了解股东人数信息，敬请携带最近的有效持股证明及身份证明，由股东本人联系公司董事会办公室办理查阅事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100021249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","LU2328871848.SGD","BK0183","000963","BK0132","BK0188","BK0175","BK0196","BK0187","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836746","title":"华东医药：公司正在应FDA要求，将和FDA进一步讨论HDM2005三期方案设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664836746?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:03","pubTimestamp":1788246199,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，2005获得了FDA的快速通道资格，请问下该药预计在美国什么时候启动临床，预计会自己推动吗还是华东医药回复：您好！公司正在应FDA要求，将和FDA进一步讨论HDM2005三期方案设计。在相关事项明确后，公司将根据项目情况选择海外临床开发路径，海外具体启动时点将结合国内临床数据、海外市场及资源情况综合确定，如进入实质推进阶段，公司将及时披露。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100021223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1969619763.USD","BK0132","000963","BK0188","BK0187","LU2328871848.SGD","BK0183","BK0175","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882712","title":"邦顺制药赴港IPO，创始团队出自华东医药，面临诺华、泽璟制药的竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882712","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882712?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:21","pubTimestamp":1788229285,"startTime":"0","endTime":"0","summary":"两年半累计亏损4.67亿","market":"fut","thumbnail":"https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6439376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4007","LU1969619763.USD","BK0132","FRHC","LU2328871848.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4588","IE0002141913.USD","BK0183","000963","01477","BK0209","BK4578","PPH","BK1574","BK0175","BK1191","BK0187","NVS","BK4532","BK0188","LU0320765489.SGD","IE00BJJMRZ35.SGD","BK0196","KCE","LU0208291251.USD","REDS","IE0009355771.USD","MEDX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0070302665.USD","IPOS","BK4585","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487881","title":"国金证券：给予华东医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664487881?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:48","pubTimestamp":1788223701,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对华东医药进行研究并发布了研究报告《医药工业整体稳健，创新研发持续推进》，给予华东医药买入评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为42.02。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100008354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662730705","title":"华东医药（000963）披露2026年半年度报告，8月27日股价上涨1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662730705","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662730705?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:22","pubTimestamp":1787826178,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，华东医药报收于27.68元，较前一交易日上涨1.35%，最新总市值为485.43亿元。该股当日开盘27.53元，最高27.88元，最低27.34元，成交额达4.42亿元，换手率为0.91%。华东医药于近日披露《2026年半年度报告》。公告显示，报告期内公司实现营业收入220.67亿元，同比增长1.81%；归属于上市公司股东的净利润18.61亿元，同比增长2.53%；扣除非经常性损益后的净利润18.58亿元，同比增长5.44%。基本每股收益1.0610元，稀释每股收益1.0610元，加权平均净资产收益率7.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700044287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0175","BK0187","BK0132","LU2328871848.SGD","BK0196","000963","BK0209","BK0188","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703345","title":"华东医药(000963)6月30日股东户数10.02万户，较上期增加18.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703345","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703345?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:05","pubTimestamp":1787825105,"startTime":"0","endTime":"0","summary":"证券之星消息，近日华东医药披露，截至2026年6月30日公司股东户数为10.02万户，较3月31日增加1.59万户，增幅为18.85%。在化学制药行业个股中，华东医药股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，华东医药区间跌幅为18.69%，在此期间股东户数增加1.59万户，增幅为18.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0209","BK0132","BK0187","LU1969619763.USD","000963","BK0183","BK0175","BK0188","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662263744","title":"股市必读：华东医药新发布《关于全资子公司获得医疗器械注册证的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662263744","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662263744?lang=zh_cn&edition=full","pubTime":"2026-08-27 04:24","pubTimestamp":1787775852,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，华东医药报收于27.31元，上涨0.11%，换手率0.9%，成交量15.77万手，成交额4.31亿元。公司公告汇总：全资子公司自研创新药注射用HDM2005获美国FDA快速通道资格，为国内首款靶向ROR1的ADC在研产品。公司公告汇总关于全资子公司药物获得美国FDA快速通道资格的公告2026年8月26日，华东医药全资子公司杭州中美华东制药有限公司收到美国FDA认证函，其自研创新药注射用HDM2005获美国FDA快速通道资格，适应症为复发/难治性套细胞淋巴瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700009756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0132","09996","BK0175","BK0188","LU2328871848.SGD","159883","BK0183","BK0209","BK0196","000963","BK1574","BK1100","BK0187","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662719085","title":"华东医药：全资子公司药物获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2662719085","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662719085?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:28","pubTimestamp":1787747322,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0183","000963","LU2328871848.SGD","BK0175","LU1969619763.USD","BK0132","BK0187","BK0209","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662171390","title":"华东医药最新公告：2026年半年度净利润同比增长2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662171390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662171390?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:01","pubTimestamp":1787742067,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)发布2026年半年度报告，实现营业收入220.67亿元，同比增长1.81%；归属于上市公司股东的净利润18.61亿元，同比增长2.53%。公司拟每10股派发现金红利3.5元(含税)。注：公司Q2净利润8.59亿，Q1净利润10.02亿，据此计算，Q2净利润环比下降14%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600042963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662734679","title":"华东医药：全资子公司获含利多卡因注射用交联透明质酸钠凝胶医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734679","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662734679?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:10","pubTimestamp":1787659850,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159883","BK0187","LU2328871848.SGD","BK0196","BK0183","BK0209","000963","BK0175","BK0188","LU1969619763.USD","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661471265","title":"8月21日华东医药跌6.08%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661471265","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661471265?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:43","pubTimestamp":1787301809,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日华东医药跌6.08%，收盘报28.1元，换手率3.16%，成交量55.31万手，成交额15.7亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0132","000963","BK0175","159316","LU1969619763.USD","BK0196","BK0209","LU2328871848.SGD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433105","title":"华东医药（000963）披露变更公司网址公告，8月17日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433105?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:05","pubTimestamp":1786975502,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，华东医药报收于29.44元，较前一交易日下跌0.94%，最新总市值为516.3亿元。该股当日开盘29.65元，最高29.71元，最低28.7元，成交额达8.61亿元，换手率为1.68%。近日，华东医药股份有限公司发布关于变更公司网址的公告。公告显示，公司根据业务发展需要，对公司网址进行变更，原网址www.eastchinapharm.com变更为www.huadongmedicine.com。新网址已正式启用，公司办公地址、投资者联系电话、传真、电子信箱等其他联系方式保持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0132","BK0183","000963","LU2328871848.SGD","BK0188","BK0175","BK0196","BK0209","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106685","title":"华东医药：提议向全体股东每10股派3.50元人民币现金（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106685","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660106685?lang=zh_cn&edition=full","pubTime":"2026-08-17 09:15","pubTimestamp":1786929310,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药08月17日在投资者关系平台上答复投资者关心的问题。谢谢华东医药回复：您好！为切实回馈股东、传递管理层长期发展信心，公司近期发布《关于公司董事长提议实施2026年中期利润分配方案的公告》，在符合相关法律法规及《公司章程》规定的利润分配政策前提下，提议向全体股东每10股派3.50元人民币现金（含税），以公司目前总股本计算，预计2026年中期分红总额为613,807,896.80元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700002615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["MUCmain","000963","UCmain","BK0196","MCNHmain","BK0209","LU1969619763.USD","LU2328871848.SGD","CYB","BK0175","BK0187","CNHmain","BK0183","BK0188","BK0132"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789038079999,"stockEarnings":[{"period":"1week","weight":-0.0055},{"period":"1month","weight":-0.0894},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.2112},{"period":"1year","weight":-0.3465},{"period":"ytd","weight":-0.3016}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0038},{"period":"3month","weight":-0.0089},{"period":"6month","weight":-0.0351},{"period":"1year","weight":0.0379},{"period":"ytd","weight":-0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100196人(较上一季度增加18.85%)","perCapita":"17495股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}